Pharmaceutica Analytica Acta

Vincenzo Ravo

Publications

• Research Article
  Oral Mucositis related to Radiotherapy for Head and Neck cancer: Evaluation of the Effectiveness of a New Anti-inflammatory Product Containing Verbascoside, Polyvinylpyrrolidone, Hyaluronic Acid (Mucosyte)
  Author(s): Rossella Di Franco, Matteo Muto, Vincenzo Ravo, Domenico Borrelli, Alfonsina Pepe, Sara Falivene, Angela Argenone, Giovanna Guida and Paolo MutoRossella Di Franco, Matteo Muto, Vincenzo Ravo, Domenico Borrelli, Alfonsina Pepe, Sara Falivene, Angela Argenone, Giovanna Guida and Paolo Muto
  
  Introduction: Mucositis is a greater complication of chemotherapy and radiotherapy in head and neck cancer, linked with risk of interruption of therapy. Toxicity is related to reactive oxygen species, which cause transcription ofNF-kB, iNOS, AP-1, pro-inflammatory cytokines. Objectives: We have conducted a retrospective study to evaluate the preventive effect of Verbascoside (Mucosyte�) in the onset of mucositis due to radiotherapy. Methods: We evaluated 172 patients treated with radiotherapy, divided in two arms: Control Group of 83 patients treated with 3DCRT or IMRT and with Verbascoside (Mucosyte�) prescribed at appearance of mucositis, and on the other hand Mucosyte Group of 89 patients treated with 3DCRT, IMRT, Tomotherapy who received Mucosyte� previously and until two weeks from the end of radiotherapy. Radiotherapy doses were between 30-71.3Gy delivered with multiple co.. View More»
  DOI: 10.4172/2153-2435.1000312

  Abstract PDF